Narinder Pal Bhalla - 13 Feb 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Medical Officer
Signature: /s/ Carole Rosenberg, Attorney-in-Fact
Issuer symbol: LXEO
Transactions as of: 13 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Feb 2026, 16:55:06 UTC
Previous filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bhalla Narinder Pal	Chief Medical Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK	/s/ Carole Rosenberg, Attorney-in-Fact	17 Feb 2026	0002109299

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Award	$0	+49,500		$0.000000	49,500	13 Feb 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXEO	Stock Option (right to buy)	Award	$0	+297,000		$0.000000	297,000	13 Feb 2026	Common Stock	297,000	$6.31	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2	Includes 49,500 RSUs.
F3	25% of the shares underlying the option vest and become exercisable on January 20, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.